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ABSTRACT 
Mannheimia haemolytica (M. haemolytica)-induced bovine respiratory disease causes millions of 
dollars in economic losses to Canadian cattle industry. Contemporary management strategies 
built around the use of antimicrobials are proving to be increasingly unavailing and lead to drug 
residues in meat which may contribute to the development of multi drug resistant bacteria. Many 
M. haemolytica vaccines are effective in stimulating antibody responses but studies of vaccina-
tion in young calves and the cattle exposed to M. haemolytica (high-risk cattle) have shown poor 
vaccine efficacy. Antimicrobial peptides (AMPs) may help in the management of respiratory 
disease caused by M. haemolytica while minimizing the risk of drug residues in animal-derived 
food products.  
AMPs are positively charged molecules that can kill bacteria primarily through the electrostatic 
interactions with the anionic bacterial lipid bilayer. Since the primary target of AMPs is the bac-
terial surface charge, which is evolutionarily conserved, the development of resistance towards 
AMPs seems less likely. These peptides hold potential to replace or reduce the use of antibiotics.   
Human β-Defensin 3 (HBD3) and Microcin J25 (MccJ25) are cationic peptides that have shown 
good activity against many Gram-negative bacteria. Five peptides, namely native HBD3, three 
synthetic HBD3 analogues (28 amino acid, 20AA, and 10AA), and MccJ25 were selected for 
microbicidal activity against M. haemolytica. Three C-terminal analogues of HBD3 with all 
cysteines replaced with valines were manually synthesized using solid phase peptide synthesis 
(SPPS).  
In the three analogues, replacement of cysteine with valine rendered them linear and increased 
their antibacterial activity. Minimum Bactericidal concentration (MBC) assays were performed 
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with the final inoculum size of 1-5x10
5 
cells/ml, with the exception of the 10AA analogue which 
was incubated with 10
4 
cells/ml final inoculum size. The antimicrobial assay showed that M. 
haemolytica was intermediately sensitive to HBD3, 28AA and 20AA analogue with an MBC of 
50 µg/ml. MccJ25 had limited effect with an MBC greater than 100 µg/ml. The MBC value of 
6.3 µg/ml achieved with the 10AA analogue is likely a result of lower final inoculum size. 
AMPs have several immunomodulatory functions, and these peptides can act as chemoattractant, 
induce cytokine release that in turn leads to chemotaxis of monocytes and neutrophils. Since 
neutrophils play an important role in the pathogenesis of BRD, the chemotactic effect of HBD3, 
20AA and 28AA peptides on bovine neutrophils was studied using Boyden chamber. Peripheral 
blood neutrophils isolated from normal healthy cattle showed chemotaxis towards HBD3 and 
20AA peptides (P<0.05) but not towards 28AA analogue. Co-incubation of neutrophils with any 
of the peptides did not affect their chemotaxis towards N-formyl-L-methionyl-L-leucyl-
phenylalanine (fMLP).  
Based on these data, it can be concluded that HBD3 and its analogues showed antimicrobial ef-
fects against M. haemolytica but MccJ25 had limited microbicidal activity against M. 
haemolytica. While HBD3 and 20AA analogue were chemotactic for bovine peripheral blood 
neutrophils, none of the peptides inhibited fMLP-induced migration of neutrophils. These pep-
tides hold potential for further in vivo testing to develop them for use to manage M. haemolytica-
induced respiratory disease in cattle. 
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1.  INTRODUCTION  
1.1.  Background 
Canada’s beef-producing industry and cattle sector are major contributors to the Canadian econ-
omy. According to Canada Beef Inc., Canada has nearly 83,000 cattle farms and ranches and this 
sector contributes upwards of $20 billion a year to Canadian economy. The beef and dairy cattle 
industry suffer significant economic losses due to Mannheimia haemolytica (M. haemolytica)-
induced Bovine respiratory disease (BRD) [1]. M. haemolytica, a Gram-negative coccobacillus, 
which causes pneumonia in cattle, resides in the nasopharynx of cattle in a commensal relation-
ship, but stress and viral infections compromise host defenses giving M. haemolytica an oppor-
tunity to penetrate lungs and cause infection [2]. A variety of vaccines and antibiotics against M. 
haemolytica are available but control and prevention is still a problem and due to which approx-
imately $1 billion per year are lost by the US cattle industry [1-5] with similar relative losses  
the in Canada.  Problems such as antibiotic resistance, antibiotic residue in meat and an inade-
quacy of vaccines push for the search of alternative treatments. 
In this context, antimicrobial peptides (AMPs) have received significant attention as alternatives 
to antibiotics [6, 7]. Human β-Defensin 3 (HBD3) has been isolated from airways surface fluid 
from patients with psoriasis, suggesting it may play a role in fighting local infection [8]. Coupled 
with the fact that M. haemolytica, in normal condition, is prevented from entering into the lungs 
by the host’s innate defense mechanism which includes the bovine defensins [2], it was thought 
that HBD3 peptide might be effective in M. haemolytica-induced pneumonia. Microcins are an-
other class of AMPs which are produced by bacteria such as E. coli. Microcins inhibit the growth 
of many pathogenic Gram-negative bacteria with Minimum inhibitory concentration (MIC), in 
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the nanomolar range [7, 9-11]. Specifically, MicrocinJ25 (Mccj25) is a peptide comprised of 21 
amino acids and is active against many Gram-negative bacteria such as E. coli and Salmonella. 
Mccj25 is stable in the presence of many proteolytic enzymes because of its unique lasso like 
structure [7]. Therefore, we hypothesize that HBD3 and Mccj25 might prove as potential candi-
dates for application in the treatment of BRD. The objective of the current study was to design, 
synthesize, purify and evaluate the antimicrobial activity of HBD3 its analogues, and recombi-
nant MccJ25 against M. haemolytica. 
1.2.  Pathophysiology of Mannehemia haemolytica induced Bovine Respiratory Disease 
Multiple factors such as viral infections with bovine herpes virus-1, and stress caused by wean-
ing and transportation may contribute to the progression of bovine respiratory disease [2, 5]. 
Although the mechanism by which susceptibility to M. haemolytica increases is still unclear 
some studies have suggested that during viral infections leukocyte function is altered [2, 4, 5, 
12].  
In healthy cattle the non-pathogenic serotypes of M. haemolytica S2 and S4 are most numerous, 
while pathogenic serotype S1 is low in number [13]. Factors such as weaning, mixing of cattle 
with various health conditions in the feedlot, transportation stress and micro-environmental 
changes induced by viral infections, may augment multiplication and colonization of the naso-
pharyngeal region by M. haemolytica serotype S1 [14]. Although the mechanism is not fully un-
derstood, BRD develops after S1 serotype preferentially colonizes the upper respiratory tract, 
where its further proliferation promotes its entry of into the trachea and lungs [14, 15].  
M. haemolytica S1 evades the host immune system and colonizes lungs with the help of several 
virulence factors such as Capsule, adhesins, outer membrane proteins, lipopolysachharides 
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(LPS), leukotoxin (LKT), neuraminidase and glycoprotease [2, 3]. LKT and LPS are the most 
important virulence factors involved in the pathogenesis of BRD [2, 5, 15-17].  
Leukotoxins derived from M. haemolytica play an important role in the development of pulmo-
nary necrosis and pathogenesis of inflammation. Leukotoxin action in ruminants [18, 19] is in-
duced through its interactions with the β2 integrin LFA-1 (lymphocyte function–associated anti-
gen 1; CD11a/CD18) expressed on many host cells. Most cells express integrins, which play sig-
nificant role in the intercellular communication and also as a communicator between a cell and 
extracellular matrix. Various leukocytes such as T lymphocytes, neutrophils, phagocytes and 
dendritic cells exclusively express β2 integrin, a subtype of integrin family [5, 20-24]. 
In vivo and in vitro results suggest that viral infections make the leucocytes more susceptible to 
the effects of M. haemolytica LKT by augmenting LFA-1 expression on bovine neutrophils and 
peripheral blood mononuclear cells via the release of mediators such as IL-1β, IFN-γ [4, 5] 
(Figure 1.1). Low concentration LKT triggers respiratory burst or degranulation in the neutro-
phils and macrophages. Proinflammatory mediators such as IL-1, IL-8 and TNFα are released 
from the activated macrophages and neutrophils, and histamine is released from mast cells. 
Higher concentrations of LKT or when leucocytes are exposed to a low to medium concentra-
tions of LKT but for greater time period results in apoptosis, cell necrosis and osmotic lyses of 
the leucocytes [22, 25-27]. Activated neutrophils and macrophages release oxygen radicals, and 
they release their intracellular proteases following their necrosis exacerbates the existing in-
flammation [5, 28-30].  
Although a major focus has been the role of alveolar macrophages in bovine respiratory disease, 
depletion of pulmonary intravascular macrophages attenuate lung inflammation due to reduced 
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expression of IL-8 and lesser accumulation of platelets in microvessels of lung [31].  Because of 
the complex interactions of viruses, bacteria and environmental factors, the pathophysiology of 
bovine respiratory disease is yet to be fully elucidated.  
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Viral infection
Inflammatory cytokines
Stimulation of LFA-1 on leukocytes 
Increased binding of M. haemolytica LKT
Activation of leukocytes with release of enzymes           Leukocyte death (apoptosis, necrosis)
Severe Pneumonia
 
Figure 1.1. Working model of how viral infection might lead to increased susceptibility of bo-
vine leukocytes to M. haemolytica [4]. 
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1.3. Antimicrobial Peptides 
Antimicrobial peptides (AMPs) play an indispensable role in innate immunity against various 
microbes such as fungi, viruses, Gram positive and Gram negative bacteria. These small cationic 
peptides have acted as the primary defense mechanism for most living organisms for over 2.6 
billion years [32-34]. The primary mode of their action is disruption of bacterial cell membrane 
[35-43]. AMPs are positively charged and show a preference for bacterial membrane over mam-
malian cell membrane because bacteria are rich in anionic lipids such as phospahtidyl glycerol, 
have high transmembrane potential and do not possess cholesterol. Because they lack both net 
charge and cholesterol and also have a weaker transmembrane electric potential compared to 
bacterial cell membrane, mammalian cell membranes are relatively resistant to AMPs killing ac-
tion [35-44] Two mechanisms of cell membrane disintegration have been proposed. 1) Barrel 
stave, accounts for a few peptides that are nonselective lytic peptides (lytic for both mammalian 
and bacteria cells) (Figure 1.2) [45-47]. 2)   Carpet mechanism, is responsible for a wider catego-
ry of peptides which are selective for bacteria (Figure 1.3), respectively [38].  
The peptides that act through Barrel stave mechanism interact with the target membrane (inner 
cell membrane) via hydrophobic interactions. These peptides must form assortment of 
transmembrane pores by recognizing each other while in the membrane bound state and addi-
tional peptide monomers continue to associate with and increase size of the pore. While α-helical 
peptides must be approximately 22 AA in length, those with β-sheeted structure must be approx. 
8AA long. Because transmembrane potentials of microbes is depleted by only a few pores, the 
peptides acting through Barrel stave mechanism are active at nanomolar concentrations [38]. 
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Peptides working via the Carpet model do not self associate while membrane-bound. Most pep-
tides act via the Carpet model which is suggested by the fact that many peptides with different   
length and amino acid composition act at the same molar concentration [38, 48-56].  
Ever increasing bacterial resistance towards most of the prevalent antibiotics continues to pro-
vide impetus for the search of novel therapies. Although a plethora of new antibiotics such as β-
lactams, glycopeptides, macrolides, ketolides, and aminoglycosides have been developed, the 
threat of increased bacterial resistance makes it imperative to continue the search for newer ap-
proaches and to supplement the existing drugs [57, 58].   
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(A) Peptides monomers or oligomers assemble on the surface of the membrane (B), peptides en-
ter lipid core of the membrane after employing more monomers.“Blue, hydrophobic surface; red, 
hydrophilic surface” [38]. 
 
 
(A) The positively charged peptides, in the form of monomers or oligomers, cover the membrane 
like a carpet such that their hydrophobic surfaces face the membrane and their hydrophilic sur-
faces are faced towards the solvent (B) Peptides reach a certain minimum concentration, infil-
trate the membrane and form fleeting pores (C) Membrane is ruptured due to disruption of bi-
layer curvature. Blue: Hydrophobic surface; Red: Hydrophilic surface [38]. 
 
 
Figure 1.3. The proposed carpet model for membrane permeation.  
 
  
Figure 1.2. The barrel-stave model for pore formation in the membrane.  
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AMPs have a conserved three-dimensional structure, which may be critically required for anti-
microbial activity [51, 57-61]. This common structure can be modified in a variety of ways to 
develop new AMPs for the cure and prevention of several ailments. Therapeutically, AMPs can 
be used alone or in synergy with other antibiotics or antiviral for enhanced effect [35]. AMPs can 
stimulate the immune system by inducing innate immunity and neutralizing endotoxins [38]. 
There are several peptides in Phase II and Phase III clinical trials and in the market, such as 
XMP.629, Omiganan (MBI-226) and Enfuvirtide.  XMP.629 (Xoma LLC, Berkeley, CA, USA) 
were found to be active against P. acnes with MBC between 0.5 to 4.0 μg/ml. Topical dermal 
application of XMP.629 was found safe in a Phase I clinical trial, but a clear benefit was not 
found in a Phase II clinical trial involving 253 patients receiving topical therapy of acne.  
Omiganan (MBI-226) (Microbiologix Biotech, Vancouver, BC, Canada) obtained from bovine 
neutrophils is a cationic peptide proven to be a broad-spectrum antibiotic and antifungal agent in 
vitro [36, 43]. Omiganan was administered in a Phase III clinical trial to patients suffering from 
bloodstream infections. However, Omiganan did not produce a statistically significant reduction 
in the infection levels compared to povidone iodine (control) [43]. Enfuvirtide (INN) inhibits 
HIV fusion and is in clinical use for the treatment of HIV-1 infection in combination with other 
antiretroviral. 
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1.3.1.  Neutrophils and Antimicrobial Peptides 
Mammalian cell membrane is affected by AMPs in many ways. AMPs can affect the quicker 
resolution of infection and wound healing by stimulating cellular processes such as chemotaxis, 
angiogenesis and cytokine release. AMPs can also participate in antigen presentation. 
AMPs such as LL37 can act in synergy with other peptides and enzymes such as lysozymes. 
LL37 in the presence of BD2 results in quick resolution of infection. AMPs are active in vivo 
under normal conditions at much lower MIC than when tested in vitro. One such example is 
LL37, which has a MIC greater than 32 μg/ml against E. coli in vitro but the in vivo active con-
centration of LL37 is less than 2 μg/ml.  
There is a growing body of evidence indicating that AMPs act through indirect mechanisms to 
provide protection such as through stimulation of chemokine or cytokine production or influenc-
ing gene expression in the host. For example, AMP can inhibit pro-inflammatory cytokine pro-
duction induced by endotoxin, promote chemokine release and modulate the responses of den-
dritic cells or T cells (Figure 1.4) [62]. The chemokine production induced by AMPs can cause 
recruitment of new inflammatory cells to the site of infection. 
Human neutrophil peptide 1 (HNP-1) and HNP-2 are α-defensins that promote the recruitment of 
monocytes to inflammatory sites through their direct or indirect chemotactic activity [63]. Simi-
lar to α-defensin AMPs, HBD3 and HBD4 are chemotactic for monocytes and macrophages [64]. 
AMPs such as HBD3 recruit leukocytes directly as well as through induction of expression of 
chemokines or cytokines such as CXCL8 (IL-8) and CCL2 (monocyte chemoattractant protein, 
MCP-1). 
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AMPs induce a variety of responses in monocytes, macrophages, neutrophils and epithelial cells. 
They alter gene expression of host cells, induce production of chemokines and cytokines, pro-
mote leukocyte recruitment to the site of infection, influence cell differentiation and activation 
and block or activate innate immune responses to induce protection against infection, selective 
control of inflammation, promotion of wound healing and initiation of adaptive immune re-
sponses. Abbreviations: AMP, anti-microbial peptide; DC, dendritic cell; LPS, lipopolysaccha-
ride; pDC, plasmacytoid dendritic cell; PMN, polymorphonuclear cells; TLR, Toll-like receptor 
[62]. 
 
 
 
 
 
 
Figure 1.4. Multiple functions of antimicrobial peptides in host defense.  
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1.3.2. HBD3, HBD3 analogues, and Microcin J25 (MCCJ25)  
HBD3 is a cationic peptide, highly basic with a high positive charge (+11) [65] and consists of 
45-amino-acids (Figure 1.5 & Figure 1.6). HBD3 has a broad spectrum antimicrobial activity and 
it may also act as a chemoattractant molecule. It is active against many Gram-negative and 
Gram-positive bacteria. Its antimicrobial activity not only depends upon the overall hydrophobi-
city and charge but, also on their overall distribution [66]. HBD3 has disulfide bonds that are re-
sponsible for its chemotactic property; disulfide bonds promote chemotaxis by activating the 
chemotaxis receptors and by increased binding. However, HBD3 disulfide bonds do not have 
any antimicrobial function. HBD3 kill bacteria by causing perturbations in bacterial membrane, 
via electrostatic interactions with negatively charged bacterial cell membrane [67]. 
HBD3 does not require disulfide bridges to mediate its antimicrobial activities, however they re-
sponsible for proinflammatory chemotactic properties and therefore may contribute to side-
effects [65]. The emergence of resistance against HBD3 seems not very likely since it acts pri-
marily by the electrostatic interaction with the oppositely charged membrane of microbes. Thus 
development of resistance to anti-microbial peptides would require microbes to change their sur-
face charge, which is evolutionarily conserved and not likely to occur [67, 68].        
Wild-type HBD3 and three peptide fragments derived from the C-terminal are used in this study. 
In the three C-terminal analogues, namely 10 amino acid (AA), 20 AA, and 30 AA, cysteine 
(Cys) residues from the wild type sequence were substituted with Valine.  It has been shown that 
substitution of the Cys residues with Tyrosine, Tryptophan or Valine retained potent  
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Figure 1.5. Amino acid sequence of HBD3. The three disulfide bonds between cysteine resi-
dues are shown. 
Figure 1.6. Ribbon diagrams of the three human β-defensin3.The three-disulfide bonds shown 
in gold [68]. 
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Figure 1.8. The ribbon representation of the lasso structure of MccJ25 is shown [70, 71]. 
 
Figure 1.7 Amino acid sequence of MccJ25. Amino acids 1 and 8 connect to form a ring. 
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anti-bacterial activity against Pseudomonas aeruginosa, a Gram-negative bacteria implicated in 
eye infections [66].  In addition, flexible analogues resulting from the removal of disulfide bridg-
es have shown reduced cytotoxicity towards host cells [65]. 
Microcin are antibiotics produced by many strains of E. coli to secure nutrients from other bacte-
ria in its vicinity. E. coli has specialized pumps to quickly secrete it. The 21 residue Microcin J25 
is one of the microcin families; it has a “lassoed tail” structure, which makes it extremely stable 
to many proteolytic and metabolic enzymes. (Figure 1.8) [69]. Out of 21 amino acids, 8 amino 
acids form a ring. The ring is formed by the formation of an isopeptide bond between the free N-
terminal amine group and amino acid residue glutamic acid which occupies the eighth position in 
the sequence [70, 71]. The remaining 13 amino acids form a loop which passes through the ring. 
Amino acids phenylalanine and tyrosine occupy 19 and 20th place in the sequence and face each 
other to maintain the loop [7, 9-11]. 
MccJ25 acts by two different mechanisms. First, it primarily inhibits transcription by obstructing 
the secondary channels of the RNA-polymerase (RNAP) and as a result prevents the access of 
the substrates to its active sites [69, 72-74]. The second mechanism of action is disrupting the 
electric potential of the target cells. MccJ25 has also been shown to inhibit oxygen consumption 
and the respiratory chain enzymes in E. coli [73]. 
1.4. Solid Phase Peptide Synthesis 
SPPS is a general method of building an amino acid (AA) chain on an insoluble resin which is 
inert to the solvents used in the process.  First, amino acid is loaded on the solid support con-
tained in a syringe (Figure 1.9). All amino acids have their alpha amino group and side chain 
protected by groups such as tertiary-butyloxycarbonyl (Boc) or 9-fluorenylmethyloxycarbonyl 
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(Fmoc) to prevent undesired amino acid polymerization [75] [76]. After adding first AA to the 
resin beads, the alpha amino group of the first amino acid, which is masked by fmoc, is 
deprotected and the resin is washed with the solvents such as DCM and DMF. The next amino 
acid is acylated (i.e. activated) and then coupled with the amino acid attached to the resin sup-
port. The whole process of deprotection and coupling is repeated until the desired peptide length 
is obtained. At the end, the peptide chain is cleaved from the resin support in a process called 
cleaving. All side chain protecting groups are also simultaneously cleaved in the process [77]. 
(An overview of SPPS process is shown in Figure 1.10) 
SPPS is carried out either by Boc or by Fmoc chemistry. Boc and Fmoc are protecting groups 
that protect Nα amino group. In Boc SPPS, the Boc group is deprotected by trifluoroacetic acid 
(TFA) and a tertiary amine is required to neutralize the free amino acid that is in the form of a 
TFA salt. Hydrogen fluoride (HF), which is a stronger acid than TFA, is used to cleave peptide 
from the resin; side chain protections are simultaneously cleaved. However, Boc chemistry has 
several disadvantages such as the repeated TFA acid treatment is deleterious as it causes unwant-
ed side reactions, HF treatment may be too harsh for some fragile sequences and HF is potential-
ly a very hazardous chemical. 
Fmoc SPPS utilizes an orthogonal concept, which means the Nα amino and side chain protecting 
groups are detached by different mechanisms because they are different chemical entities [71, 
76, 78]. The Nα amino group is protected by Fmoc and is removed in basic conditions, by 
piperidine in N, N-dimethylformamide (DMF), whereas side chain protecting groups are simul-
taneously cleaved at the time of peptide cleavage, in acidic conditions, by TFA. The milder reac-
tion conditions make Fmoc synthesis preferable over Boc chemistry [75].  
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1.4.1. Resin Support. 
Polymer matrix or resin support plays an important role in the success of SPPS. Polystyrene resin 
cross-linked with 1% of 1,3-divinylbenzene is a commonly used polymer matrix. This resin 
swells 2-6 fold when treated with DMF or dichloromethane (DCM), which is desirable character-
istic as it increases the rate of diffusion and increase the kinetics the of reaction. Greater swelling 
facilitates greater diffusion of the reagents into the matrix [78, 79]. 
A linker connects resin beads to the carboxyl group of the first amino acid. There are a variety of 
resins such as Rink, Wang, and their derivatives but we chose to use an acid labile resin called 2-
Chlorotrityl chloride resin (Figure 1.11) which is suitable for Fmoc-SPPS. The steric bulk of 2-
Chlorotrityl chloride resin prevents diketopiperazide formation when the second amino acid is 
loaded [80]. 
  
18 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Syringe like reaction vessel for manual SPPS.  
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Figure 1.10. Normal SPPS cycle, P-AA-OH represent Fmoc protected amino acid and H-AA-OH 
symbolize amino acid with a free amine [77]. 
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1.4.2. AA Coupling  
Coupling reaction means a peptide bond formation between two α-amino acids. A peptide bond 
also known as an amide bond is a bond between carboxyl group of one AA with the α-amino 
group of another. Normally a reaction between an amine with a carboxylic acid results in the 
formation of a stable salt (Scheme 1). Hence, the carboxyl group needs to be acylated i.e. acti-
vated by introduction of a leaving group 'X' and production of carboxylic acid derivatives 
(RCOX). 'X' is an electron withdrawing group which increases the susceptibility of the carbonyl 
carbon to nucleophilic attack by an amino group (Scheme 2) [81].      
Coupling reagents are used to increase yield and decrease racemization, which may occur during 
amide bond formation [81]. In our coupling reaction mixture we used (2-(6-Chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) for acylation of carboxyl 
to give active ester while hydroxybenzotriazole (HOBt) is used to prevent racemisation and a 
hindered or a non-nucleophilic base NMM. 
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Figure 1.11.  2- Chlorotrityl resin. 
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Scheme 1: Amide bond formation [82].  
 
 
 
 
 
Scheme 2: Activation of acid and amide bond formation [82].  
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1.4.3. Coupling Monitoring 
A Kaiser or ninhydrin test is a qualitative test that is sensitive to primary amines and is used to 
detect completion of coupling reaction. In this test, few beads of resin are taken from reaction 
vessel and mixed with 2 drops of each ninhydrin, phenol, and pyridine in a test tube. Then, this 
solution is heated for 3 min at 110 °C and color change is observed. Blue/purple resin beads are 
indicative of uncoupled amines. Pale yellow/brown color is a confirmation of completion of cou-
pling [77].  
1.4.4. Peptide Cleavage 
Trifluoroacetic acid (TFA) causes acidic conditions in the cleavage mixture lead to the release of 
the peptide in the free acid form [82]. The resin beads are shaken for about 60 minutes with a 
solution of TFA and water 95:5. Then, the syringe is drained and the filtrate collected into a glass 
flask. Cold diethyl ether (Et2O) is then added to precipitate the crude peptide mixture. After pre-
cipitation peptide is then filtered and subsequently washed with cold Et2O. Liquid in the crude 
peptide mixture is then evaporated on rotavapor and the crude peptide mixture is dissolved and 
lyophilized.  MALDI-TOF analysis is then performed on the lyophilized peptide. 
1.4.5. Purification and identification of peptides 
Reversed phase high performance liquid chromatography (RP-HPLC) is used for purifying crude 
peptides because it can separate peptides with very little difference in amino acid sequences. 
Various components in crude peptide mixture elute at different time and give a peak on the 
chromatogram and the substance eluted at each peak were tested by MALDI-TOF mass analysis. 
The peak which has the desired molecular mass is identified and that fraction is collected to ob-
tain the desired peptide. 
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1.4.6.  Mechanism of purification  
RP-HPLC purifies a peptide based on the principle of differential partitioning, peptides partition 
between the polar mobile phase, and the hydrophobic stationary phase. Small peptides get parti-
tioned as well as adsorbed on the stationary phase, but polypeptides are only adsorbed on the sta-
tionary phase [83] ( Figure 1.12). When the concentration of organic modifier (e.g. acetonitrile) 
reaches a critical range, the peptide desorbs. This swiftness of desorption is what makes RP-
HPLC competent in separating peptides with very slight differences. However, in the case of 
small molecules desorption could occur slowly because, they along with being adsorbed, are also 
partitioned in the hydrophobic phase [83-85] (Figure 1.13).  
When performing Gradient elution, the concentration of nonpolar mobile phase is increased 
gradually over time. For example, organic modifier concentration is changed from 20% Acetoni-
trile (Acn) in water to 50% Acn in water in 60 minutes. This elution method helps in achieving 
precise organic solvent concentration required for a particular molecule [83].  
1.4.7. Identification of peptides 
To calculate mass of peptide analogue, the software PAWS calculates mass based on the amino 
acid sequence provided. MALDI-TOF analysis was used to detect molecular weight of the syn-
thetic analog at various time points during synthesis, to ensure proper chain elongation, and after 
completion of synthesis.  
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The hydrophobic region of the polypeptide attaches via adsorption to the surface of hydrophobic 
stationary phase and stays there until the concentration of organic solvent increases to the critical 
level and detaches the polypeptide [85].  
  
 Figure 1.12. Polypeptide in the mobile phase introduced in to the column.  
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Lysozyme desorption is most quick followed by Pentaphenylalanine, a small peptide, where as 
biphenyl, a small molecule, desorbs most gradually [85].  
  
Figure 1.13. The retention time (total time during which a peptide remain attached to the station-
ary phase) of large peptides is faster than that of a small peptide.  
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2.    HYPOTHESES  
a. Antimicrobial peptides, HBD3, HBD3 analogues and MicrocinJ25 are bactericidal against 
M. haemolytica                     
b. Unlike wtHBD3, the HBD3analogues and MicrocinJ25 will not alter functioning of neu-
trophils 
3.    OBJECTIVES   
a. To synthesize, purify and characterize analogues of HBD3 as well as over-express 
MicrocinJ25 (MccJ25) in E. coli 
b. To test the antimicrobial activity of native HBD3, synthetic HBD3 analogues, and MccJ25 
against M. haemolytica 
c. To study the effect of native HBD3, synthetic HBD3 analogues, and MccJ25 on normal 
neutrophils 
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4. RATIONALE  
There is a need to develop newer antimicrobial compounds because of the concerns of antibiotic 
residues in cattle derived food products, development of antimicrobial resistance and lack of ef-
fective therapeutic and prophylactic compounds against M. haemolytica  induced lung inflamma-
tion. 
We propose to design and synthesize antimicrobial compounds belonging to Microcin and hu-
man β-defensin3 and to evaluate their antimicrobial activity against M. haemolytica, in vitro. Be-
cause neutrophils are central to host defense against bacteria, it is important that the new antimi-
crobial compounds do not have deleterious effects on the anti-microbial activities of neutrophils. 
Therefore, we will also evaluate the effects of synthesized antimicrobial molecules on neutro-
phils. 
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5. MATERIALS AND METHODS: 
5.1. Expression and Purification of Microcin J25 
Wild-type Microcin J25 (MccJ25) was used in this study as formation of the lasso ring is not 
possible synthetically.  The peptide was expressed using a high copy number plasmid pTUC202 
(a gift from Rutgers University USA), which carries the MccJ25 biosynthetic gene cluster, in 
competent E. coli MC4100 cells.  It was grown in 2L M9 minimal media for 18 h at 37
0
C. The 
culture supernatant was obtained by centrifugation at 4000 g for 15 minutes, and then subjected 
to two successive purification steps. First, it was applied on the flex column filled with XAD16 
resin (Aldrich, CA). Two successive elution steps were performed with (30:70, v/v) and (80:20, 
v/v) methanol/water mixtures. MccJ25 is eluted in the (80:20, v/v) methanol/water mixture.  
MccJ25 was purified using reversed-phase HPLC (Varian Prostar 210, U.S). The purity of the 
peptides was confirmed by MALDI-TOF mass spectrometry.  
5.2. Synthesis and Purification of HBD3 Analogues  
HBD3 fragments were synthesized manually on 2-chlorotrityl chloride resin (0.2 mmol, 1 
mmol/g).  The first amino acid was coupled using DIPEA for 5 hours.  Further amino acids were 
coupled at 2-fold excess using HCTU/HOBT/NMM as activating mixture in DMF.  Amino acid 
coupling was performed for 3 hours at room temperature to ensure the completeness of the reac-
tion, followed by Fmoc group deprotection using piperidine in DMF.  These two reactions were 
repeated until assembly of the peptide was complete.  A Kaiser test was performed after coupling 
of each amino acid.  After completion of the synthesis, peptides were cleaved from the resin and 
all protecting groups were removed using cleavage mixture at room temperature.  Cleaved pep-
tide was concentrated by rotary evaporation.  Cold ether was added to precipitate the peptide and 
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crude peptide was isolated after centrifugation.  Crude peptides were dissolved in water and puri-
fied using reversed-phase HPLC (Varian Prostar). The purity of the peptides was confirmed by 
MALDI-TOF mass spectrometry.  
5.3. Antimicrobial activity testing of peptides 
Wild-type HBD3, its analogues, and MccJ25 were tested against M. haemolytica using optical 
density method and colony count assay. Briefly, an aliquot (5 µl) from bacteria suspension stored 
at -80
o
C was put in 5 ml BHI broth at 37
o
C for 18 hours. An aliquot (10 µl) from this overnight 
culture was added to fresh BHI broth and incubated at 37
o
C for a further 5 hours to obtain mid-
log phase bacteria. The culture was then centrifuged for 10 min at 800 g at 4
0
C. The supernatant 
was discarded and the bacterial pellet was resuspended in cold, sterile sodium phosphate buffer 
(SPB) and washed again at 800 g for 10 minutes at 4
o
C. The pellet was resuspended in 5ml SPB. 
To calculate the number of CFU/ml in the 5 hour culture, six successive 10 fold dilutions were 
made. From the last dilution 100 µl was plated in duplicate on petri dishes containing BHI agar 
and incubated for 24 hours. After 24 hours the colonies were counted in the two petri dishes and 
then averaged. Total number of colonies was the average number of colonies multiplied by the 
dilution factor.  
All assays were carried out in sterile 96-well polypropylene flat-bottomed plates using a broth 
microdilution method. Two-fold serial dilutions of peptide were made in SPB, and 50 µl of each 
concentration of peptide was added to the wells of the assay plate. Fifty µl (25000 cells) of the 
bacterial suspension adjusted to 5x10
5
 cfu/ml in incubation media was prepared by adding 200 µl 
of BHI broth in 6.8 ml SPB and added to each well. Positive control wells contained 50 µl of the 
bacteria with 50 µl of 64 µg/ml ampicillin and negative control wells contained 50 µl of SPB and 
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50 µl bacterial suspension. Sterility control well contained 100 µl BHI broth to test and ensure 
that broth was not contaminated (Figure 5.1)  
The plates were sealed with aluminum foil and were incubated at 37
o
C for 2 hours then 50 µl of 
the contents of the well were pipetted on BHI agar plates and incubated for 24 hours. The bacte-
ricidal activity was expressed as the MBC which is the concentration at which 99.9% of the col-
onies are killed and the Lethal dose 50 (LD50) at which 50% or more bacteria are killed [51-53]. 
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Figure 5.1. Layout of the setup of a polypropylene 96 well plate for antimicrobial susceptibility 
testing. 
The doubling dilutions (100 μg/ml to 0.8 μg/ml) of an antimicrobial peptide were incubated with 
the peptide. B: Bacteria (M. haemolytica) and peptide incubated together in one well; NC: Nega-
tive control (M. haemolytica only); SC: Sterility control (broth only); PC: Positive control (M. 
haemolytica with ampicillin). 
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5.4.  NEUTROPHIL ISOLATION AND CHEMOTAXIS ASSAY 
5.4.1. Neutrophil Isolation 
Neutrophils were isolated from cattle using established methods [86]. For each individual ani-
mal, blood was pooled into 50 mL tubes and diluted with an equal volume of PBS then 12.5 mL 
of the diluted blood was layered over 10 mL of Ficoll Paque PLUS while taking care to preserve 
the interface between the two liquids. Following centrifugation at 400 g for 30 minutes at 20
o
C 
with the brake turned off, the lymphocyte layer was discarded along with Ficoll and plasma. The 
pellet was washed in 20 ml PBS with centrifugation at 500 g with low brake for 10 minutes. The 
supernatant was discarded and the pellet was suspended in equal volume of sterile water and 
gently mixed for 20 seconds followed by addition of equal volume of 1.8% NaCl to restore to-
nicity. The mixture was centrifuged at 500 g for 10 minutes and followed by another washing 
and centrifugation at 4
0
C. The resulting neutrophil pellet was resuspended in PBS. Bovine neu-
trophils, collected in the above manner had more than 92% purity, and their viability was greater 
than 95% based on Trypan blue exclusion assay. 
5.4.2. Chemotaxis assay 
fMLP (114 nm)  was used as the chemoattractant. Approximately 25 μl of peptides (50 μg/ml) 
was put into lower compartment wells of a 48-well Boyden Chamber. After the fMLP loading, 
the polycarbonate membrane filter (pore size 5 μM), with the shiny side up, was placed over the 
lower chamber.  Next, silicone gasket was placed on the membrane, then the upper chamber was 
put on top of the gasket and the lug nuts firmly secured. Cell suspension (1 X 10
6
 cells) was then 
placed over control wells and N/P wells (neutrophil at top and peptide in the bottom wells). The 
whole assembly was then incubated at 37°C in humidified air with 5% CO2 for 20 minutes. After 
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the incubation, the Boyden chamber was disassembled and the membrane carefully held with the 
bulldog clamp and the cells on the upper shiny surface scraped with the wiper blade. Next, the 
filter membrane was stained with the Diff-Quick and mounted on glass slide with the bottom 
side up. The cells within the filter pores were then counted in 5 random fields under light micro-
scope at 40 X.  The results are presented as the number of migrated neutrophils per microscopic 
field. 
5.4.3. Migration inhibition Assay 
Since peptides can be immunomodulatory, migration inhibition was carried out to determine if 
the peptides inhibit neutrophil migration. This assay was performed in the same manner as the 
chemotaxis assay with the only difference being that peptide and neutrophils were incubated to-
gether on the top of the filter; 25 μl of 100 μg/ml peptide and 25 μl (2 X 106 cells) of neutrophils 
were put together. In the lower wells 25 μl of 114 nM fMLP (chemoattractant) was placed fol-
lowed by the staining and counting of the cells as described above.  
5.5. Statistical Analysis  
Data from susceptibility testing assay was analyzed using the non-parametric statistics (using 
ranked data), because the data were variable among groups most likely due to small sample size. 
The comparisons were done using contrasts (1 compared to 2, 2 compared to 3, and so on), given 
that we expected a decrease in colony count with increasing concentrations. Groups were consid-
ered statistically significant if the P-value was less than 0.05. A One-way ANOVA followed by 
Dunnets Multiple Comparisons test was performed on data obtained from the chemotaxis and 
migration inhibition assay. Significance was recorded when P<0.05. Computer software 
GraphPad Prism 6 and SPSS for migration and susceptibly assays, respectively, were used. 
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6.  RESULTS 
6.1. Peptide Design and Synthesis 
Five peptides, Microcin J25 (MccJ25), HBD3, 10AA HBD3, 20AA HBD3 and 28AA HBD3 
were evaluated in this study.  Because wild type HBD3 is commercially available, we purchased 
it at 95% purity (AnaSpec Inc.)  The amino acid sequences of the HBD3 and its analogues stud-
ied are shown in (Figure 6.1).  
Approximately 3 mg Wild-type MccJ25 was obtained by over expression protocol already estab-
lished by Kaur and colleagues [87].  After purification by flex column the crude MccJ25 was fi-
nally purified with the C-18 RP-HPLC, at a flow rate of 2 ml/min 55-80% methanol/water mix-
ture in 55 minutes. Various fractions at different time points were obtained. Fraction containing 
the desired mass for MccJ25 eluted at 20 minutes on the RP-HPLC column. The calculated mass 
for MccJ25 was 2107 MW and the mass was determined to be [M+H]
+ 
2107.7 (Figure 6.2). The 
elute from desired peak was collected, pooled and lyophilized. The yield or the concentration of 
MccJ25 was measured using UV-Vis spectrophotometer at 278 nm. 
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Figure 6.1 Amino acid sequences of HBD3, and the three HBD3 fragments.  Substitution of cys-
teine residues with valine in the fragments is shown in red. 
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Figure 6.2. a) HPLC chromatogram of crude Microcin J25 (MccJ25) showing elution of MccJ25 
at 20 min following acetonitrile/water gradient on a reversed-phase column. mAU is a symbol 
for the milli-absorbance unit. b) MALDI-TOF of pure MccJ25, purified by reversed-phase 
HPLC, showing [M+H] + peak (observed 2107.7 and calculated. 2107). Intensity is relative 
abundance or signal intensity of the ions and m/z is mass to charge ratio. 
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6.1.1. SPPS Synthesis of HBD3 Analogues 
Three C-terminal HBD3 analogues were designed as short fragments of wtHBD3 with different 
amino acid chain lengths (Figure 6.1). In each analogue, cysteine was replaced with valine to 
remove di-sulfide linkages and render the fragment linear.  
Standard SPPS with Fmoc chemistry was used for the synthesis of the three analogues. Synthesis 
was carried out in a syringe like reaction vessel with a frit at the bottom. 10AA analogue was 
synthesized first. Amino acid chain was built on 2-chlorotrityl resin (0.2mmol ~ 127mg) in the 
reaction vessel. The First amino acid lysine (5eq or 1mmol) lysine was coupled using N, N-
Diisopropylethylamine (DIPEA) (1 mmol) which is 5 times the amount of resin. The amount of 
amino acids added after first amino acid was two equivalents (2eq) of the resin i.e.0.4 mmol.  
Also, all of the amino acids were added after first lysine was activated in HCTU 
(0.4mmol)/HoBT (0.4mmol)/NMM (100 μl) mixture in 1-2 ml DMF. The proper peptide chain 
elongation was ensured with Ninhydrin test after every coupling step and test cleavage after eve-
ry third amino acid.  
 After building 10AA amino acid chain, the peptide was cleaved from the solid support. A treat-
ment with 95% TFA, 5% tri-isopropylsilane in water, for 2 hour at room temperature with con-
tinuous shaking of the vessel was used to simultaneously de-protect the side chains and cleave 
the crude peptide from the resin. 
On a semi-preparative RP-HPLC column using gradient elution, 22 mg of the crude 10AA ana-
logue was purified. During method development for purification several schemes were tried such 
as 90-10% acetonitrile/water in 40 minutes at 1ml/min flow rate, with this method desired frac-
tion was found eluting with few other fractions, then a gradient of 50-20% acetonitrile/water in 
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60 minutes with the flow of 1.3ml/min and finally the used for purification was 10-35% acetoni-
trile/water in 60 mins with a flow rate of 1.3 mL/min. (Table 6.1) 
The successful method also suggests that 10AA analogue was not very hydrophobic as it eluted 
mostly at gradient with 87% water in the mobile phase. Peaks eluted at 10.9-11.2, 13.4-14.5, 17-
18, 26-27, 27-28, and 33-34 minutes were collected. Mass spec, through MALDI-TOF with α- 
cyano-4-hydroxycinnamic acid (HCCA) as a matrix, for all of the elutions was taken and elution 
at peak 13.4-14.5 had the correct mass (Figure 6.3a). Calculated mass for 10AA was 1283 and 
the mass found was [M+H] 
+
 1282.6. (Figure 6.3b) 
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Table 6.1. Gradient elution scheme for 10AA and 20AA HBD3 analogues. 
 
 
 
 
 
Time (min) Acetonitrile (%) Water (%) 
0 10 90 
30 17.5 82.5 
60 35 65 
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Figure 6.3. a) HPLC chromatogram of crude 10AA analogue showing elution of at 13.1 min fol-
lowing acetonitrile/water gradient on a reversed-phase column. mAU is a symbol for the milli-
absorbance unit. b) MALDI-TOF of pure 10AA analogue, purified by reversed-phase HPLC, 
showing [M+H]
+
 peak (found 1282.6, calculated. 1283). Intensity is relative abundance or signal 
intensity of the ions and m/z is mass to charge ratio. 
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20AA analogue was synthesized in a manner similar to 10AA analogue. Beyond the addition of 
tenth amino acid, ninhydrin test and test cleavage were performed after every third coupling.  
Double coupling was performed for the last four amino acids, because of the positive ninhydrin 
test after single coupling.  
The purification scheme used for 20AA analogue was the same as the 10AA analogue. Peaks 
eluted at 13-14.5, 23-25, 29-30, 35-36.5, and 51.5-53 minutes were collected. Similarly, the mass 
spectrum, through MALDI-TOF with α- cyano-4-hydroxycinnamic acid (HCCA) as a matrix, for 
all of the elutions was taken and the correct mass was found in elution at peak 35-36.5 (Figure 
6.4). Calculated mass for 10AA was 2384 and the mass found was [M+H] 
+
 2383.1 (Figure 6.4). 
However, complete resolution between 19AA analogue and 20AA analogue could not be 
achieved. Several other schemes were tried to achieve resolution of 20AA analogue from other 
truncated peptides but best results were achieved with 10-35% acetonitrile/water in 60 minutes 
with a flow rate of 1.3 mL/minute scheme. Nonetheless, the major component from the eluate 
was 20AA analogue and 19AA analogue was only a small fraction. Overall 24-28 mg of purified 
peptide was obtained. 
The synthesis of 30AA, linear with all cysteines mutated with valine, was attempted. However, 
the chain could be elongated only up to 28 AA analogue as identified by mass spec of crude pep-
tide showing a mass of 3386.4 [M+H] 
+
 (Calculated. 3387) (Figure 6.5).  
The coupling of glycine moiety to the 28th amino acid arginine could not be achieved even with 
three consecutive couplings. Since the manual synthesis of such a long amino acid chain is usual-
ly fraught with many pitfalls, the elongation of a 28 amino acid chain was a satisfactory result, 
because the appropriate balance of positive charge and hydrophobicity was attained. 
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Figure 6.4. a) HPLC chromatogram of crude 20AA analogue showing elution at 35 min follow-
ing acetonitrile/water gradient on a reversed-phase column. mAU is a symbol for the milli-
absorbance unit. b) MALDI-TOF of pure 20AA analogue, purified by reversed-phase HPLC, 
showing [M+H] 
+
 peak (found 2383.1, calculated. 2384). Intensity is relative abundance or signal 
intensity of the ions and m/z is mass to charge ratio. 
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Figure 6.5. : MALDI-TOF of crude 28AA analogue, showing [M+H] 
+
 peak (found 3386.4, calculated. 
3387). Intensity is relative abundance or signal intensity of the ions and m/z is mass to charge ratio. 
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6.2 Microbicidal effect of peptides 
Peptides HBD3 its analogues and Mccj25 were assessed for MBC. Minimum bactericidal con-
centration (MBC) is described as the lowest concentration of each drug that resulted in a 99.9% 
reduction in CFU of the initial inoculum. All the peptides have shown intermediate to potent kill-
ing activity towards M. haemolytica. The final inoculum size should be 5x10
5 
cfu/ml, but varied 
between 1x10
5 
cfu/ml to 1x10
6 
cfu/ml and is acceptable as per M7-A7 guidelines. However, 
some published studies have taken final inoculum in the range of 10
4 
cfu/ml to 10
5 
cfu/ml [88].   
The comparison of antibacterial activity at different concentrations of HBD3 revealed that HBD3 
was equally active at 100.0 µg/ml and 50.0 µg/ml. However, the concentrations 50 µg/ml and 
25.0 µg/ml, 25.0 µg/ml and 6.3 µg/ml  and 6.3 µg/ml and 3.1 µg/ml were statistically different. 
The concentrations 3.1 µg/ml and 0.8 µg/ml were not active and there was no statistical differ-
ence between them (Table 6.2 and Figure 6.6). 
Similar to HBD3, 20AA analogue was equally active at both 50.0 µg/ml and 100.0 µg/ml. How-
ever, the concentrations 50.0 µg/ml and 25.0 µg/ml, 25.0 µg/ml and 6.3 µg/ml and 6.3 µg/ml and 
3.1 µg/ml were statistically different from each other. Again, concentrations 3.1 µg/ml and 0.8 
µg/ml were not active and there was no statistical difference among them (Table 6.3 and Table 
6.7).  
The activity of 10AA at all the concentrations was similar without any statistical difference. It is 
worth noting that this is observed only with 10AA analogue which is very likely due to a smaller 
inoculum size (10
4 
cfu/ml) used (Table 6.4 and Figure 6.8). 
MccJ25 exhibited microbicidal effect; however the reduction in colony count was much less in 
comparison to other peptides Different concentrations of MccJ25 were compared for antibacteri-
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al activity against M.haemolytica but no statistically significant difference was observed (Table 
6.5 and Figure 6.9). 
The antibacterial effect of 28AA analogue’s concentrations 100.0 µg/ml to 6.3 µg/ml was statis-
tically similar as was the antibacterial effect for the concentrations 3.1 µg/ml-0.8 µg/ml. The on-
ly difference was observed between 3.1 µg/ml and 6.3 µg/ml (Table 6.6  and  Figure 6.10). 
Figure 6.1 shows a clear dose response when M.haemolytica was treated with crude 28AA ana-
logue. The number of colony forming units progressively increased with decreasing peptide con-
centration. The MBC and LD50 of all the peptides have been compared (Table 6.7).  While 
HBD3 and HBD3 20AA analogues have equal MBC values of 50 µg/ml, MBC value for HBD3 
28AA analogue was the lowest at 12.5 µg/ml, and MccJ25 had highest MBC value of 100 µg/ml. 
Nearly comparable LD50 values do not effectively discriminate different peptides. However, the 
value of LD50 is apparent in the fact that it shows MccJ25 kills half of the bacterial population at 
6.3 µg/ml.  
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Table 6.2. Number of colony forming units after treatment with HBD3. The tissue culture dishes 
were inoculated with 50 μl solution from the respective wells and incubated for 24 hour. (This 
table shows data from one of three separate experiments.) 
Well No. 
Peptide conc. 
μg/ml No. of CFU Well No. 
Peptide conc. 
μg/ml No. of CFU 
A1 100.0 0 B1 100.0 0 
A2 50.0 0 B2 50.0 0 
A3 25.0 31 B3 25.0 9 
A4 12.5 42 B4 12.5 101 
A5 6.3 210 B5 6.3 390 
A6 3.1 >400 B6 3.1 >400 
A7 1.6 >400 B7 1.6 >400 
A8 0.8 >400 B8 0.8 >400 
A10 - 0 B10 - 0 
A11 - 0 B11 - 0 
A12 - >400 B12 - >400 
 
Note: The final inoculum in this experiment was 5x10
5 
cfu/ml. 
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Comparisons were performed using contrasts for example 100.0 μg/ml was compared to 50.0 
μg/ml, 25.0 μg/ml compared to 12.5 μg/ml employing non-parametric statistics (ranked data).  
Statistical significance difference between two concentrations is indicated by **<0.01.  The data 
is represented as Mean±SEM.   The statistical difference between 100.0 μg/ml and 50.0 μg/ml 
concentrations was not significant but the concentration 50.0 μg/ml was statistically different 
from 25.0 μg/ml (P=0.00).   
 
 
Figure 6.6. Comparisons between microbicidal effects of eight different concentrations of 
HBD3.  
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Table 6.3. Number of colony forming units after treatment with HBD3 20 AA analogue. The tis-
sue culture dishes were inoculated with 50 μl solution from the respective wells and incubated 
for 24 hour. (This table shows data from one of three separate experiments.) 
Well No. 
Peptide conc. 
μg/ml No. of CFU Well No 
Peptide conc. 
μg/ml No. of CFU 
A1 100.0 
 
4 
 
B1 100.0 1 
A2 50.0 
 
15 
 
B2 50.0 4 
A3 25.0 128 
 
B3 25.0 151 
A4 12.5 240 
 
B4 12.5 170 
A5 6.3 289 
 
B5 6.3 261 
A6 3.1 376 
 
B6 3.1 >400 
A7 1.6 >400 
 
B7 1.6 >400 
A8 0.8 >400 
 
B8 0.8 >400 
A10 
- 
0 B10 
- 
0 
A11 
- 
0 B11 
- 
0 
A12 
- 
>400 B12 
- 
>400 
 
 Note: The final inoculum in this experiment was 5x10
5 
cfu/ml. 
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Comparisons were performed using contrasts between adjacent columns. For example 100.0 
μg/ml was compared to 50.0 μg/ml, 25.0 μg/ml compared to 12.5 μg/ml employing non-
parametric stats (ranked data).  Statistical significance difference between two concentrations is 
indicated by P value*<0.05 and **<0.01.  The data are represented as Mean±SEM. The statisti-
cal difference between 100.0 μg/ml and 50.0 μg/ml concentration was not significant. But, the 
concentration 50 μg/ml was statistically different from 25.0 μg/ml (P=0.001).  Similarly, 25.0 
μg/ml differed statistically from 12.5 μg/ml (P=0.019). P equaled 0.005 (P=0.005) when 12.5 
μg/ml and 6.3 μg/ml compared. Also there was a statistical significant difference between conc. 
3.1 μg/ml and 6.3 μg/ml (P=0.001) 
 
Figure 6.7.  Comparisons between microbicidal effects of eight different concentrations of 
20AA analogue.  
51 
 
Table 6.4.  Number of colony forming units after treatment with HBD3 10 AA analogue. The 
tissue culture dishes were inoculated with 50 μl solution from the respective wells and incubated 
for 24 hour. (This table shows data from one of three separate experiments.) 
 
Well No. 
Peptide conc. 
μg/ml 
 
No. of CFU 
 
Well No. 
Peptide conc. 
μg/ml 
 
No. of CFU 
 
A1 100.0 0 B1 100.0 0 
 
A2 50.0 4 B2 50.0 1 
 
A3 25.0 4 B3 25.0 3 
 
A4 12.5 4 B4 12.5 6 
 
A5 6.3 4 B5 6.3 1 
 
A6 3.1 7 B6 3.1 2 
 
A7 1.6 - B7 1.6 - 
 
A8 0.8 - B8 0.8 - 
 
A10 - 0 B10 - 0 
 
A11 - 0 B11 - 0 
 
A12 - >400 B12 - >400 
 
Note: The final inoculum in this experiment was 10
4 
cfu/ml. 
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The concentrations were compared using contrasts. For example 100.0 μg/ml was compared to 
50.0 μg/ml, 25.0 μg/ml compared to 12.5 μg/ml employing non-parametric stats (ranked data). 
The data is represented as Mean±SEM.  No statistical difference between concentrations was ob-
served. 
 
 
 
Figure 6.8. Comparisons between microbicidal effects of eight different concentrations of 
10AA analogue.  
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Table 6.5. Number of colony forming units after treatment with Mccj25. The tissue culture dish-
es were inoculated with 50 μl solution from the respective wells and incubated for 24 hour. (This 
table shows data from one of three separate experiments.) 
 
Well No. 
Peptide conc. 
μg/ml 
 
No. of CFU 
 
Well No. 
Peptide conc. 
μg/ml 
 
No. of CFU 
 
A1 100.0 
 
211 
 
B1 100.0 
 
275 
 
A2 50.0 
 
328 
 
B2 50.0 
 
230 
 
A3 25.0 
 
314 
 
B3 25.0 
 
310 
 
A4 12.5 
 
211 
 
B4 12.5 
 
253 
 
A5 6.3 
 
289 
 
B5 6.3 
 
261 
 
A6 3.1 
 
>400 
 
B6 3.1 
 
>400 
 
A7 1.6 
 
>400 
 
B7 1.6 
 
>400 
 
A8 0.8 
 
>400 
 
B8 0.8 
 
>400 
 
A10 
-  
0 
 
B10 
-  
0 
 
A11 
-  
0 
 
B11 
-  
0 
 
A12 
-  
>400 
 
B12 
-  
>400 
 
Note: The final inoculum in this experiment was 5x10
5 
cfu/ml. 
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Comparisons were done using contrasts. For example 100.0 μg/ml was compared to 50.0 μg/ml, 
25.0 μg/ml compared to 12.5 μg/ml employing non-parametric stats (ranked data). The data are 
represented as Mean±SEM.  No statistical difference was observed in antimicrobial activity be-
tween concentrations. 
 
  
Figure 6.9.  Comparisons between microbicidal effects of eight different concentrations of 
MccJ25.   
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Table 6.6. Number of colony forming units after treatment with HBD3 28 AA analogue. The tis-
sue culture dishes were inoculated with 50 μl solution from the respective wells and incubated 
for 24 hour. (This table shows data from one of three separate experiments.) 
 
Well No. 
Peptide conc.  
μg/ml 
 
No. of CFU 
 
Well No. 
Peptide conc.  
μg/ml 
 
No. of CFU 
 
A1 100.0 
 
0 
 
B1 100.0 
 
0 
 
A2 50.0 
 
0 
 
B2 50.0 
 
0 
 
A3 25.0 
 
10 
 
B3 25.0 
 
2 
 
A4 12.5 
 
9 
 
B4 12.5 
 
22 
 
A5 6.3 
 
56 
 
B5 6.3 
 
64 
 
A6 3.1 
 
223 
 
B6 3.1 
 
142 
 
A7 1.6 
 
>400 
 
B7 1.6 
 
>400 
 
A8 0.8 
 
>400 
 
B8 0.8 
 
>400 
 
A10 
-  
0 
 
B10 
-  
0 
 
A11 
-  
0 
 
B11 
-  
0 
 
A12 
-  
>400 
 
B12 
-  
>400 
 
Note: The final size of inoculum was 2x10
5 
cfu/ml in this experiment. 
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Comparisons were done using contrasts. For example 100.0 μg/ml was compared to 50.0 μg/ml, 
25.0 μg/ml compared to 12.5 μg/ml employing non-parametric stats (ranked data).  Statistical 
significance difference between two concentrations is indicated by *P<0.05.  The data is repre-
sented as Mean±SEM.  Only two concentrations 25.0 μg/ml and 12.5 μg/ml differed statistically 
from each other (P<0.012). 
 
Figure 6.10. Comparisons between microbicidal effects of eight different concentrations of 
28AA analogue.  
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Figure 6.11. Colony forming units of M. haemolytica; that survived after incubation with 
28AA analogue (a) at concentration 50.0 μg/ml (b) 25.0 μg/ml (c) 12.5 μg/ml d) 12.5 
μg/ml and (d) 6.3 μg/ml (e) Negative control plate and (f) positive control plate.  
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Table 6.7. Comparisons of MBC and LD50 of the peptides. MBC (Minimum Bactericidal Con-
centration) is the concentration of antibiotic at which 99.9% of the CFU in the final inoculum are 
killed and LD50 is the lethal dose for ≥ 50% of bacteria. 
 
PEPTIDE 
 
MBC (μg/ml) 
 
LD50 (μg/ml) 
 
HBD3 10AA analogue 
 
6.3 
 
≥3.1  
 
HBD3 20AA analogue 
 
50.0  
 
3.1 
 
HBD3 28AA analogue 
 
12.5  
 
3.1  
 
HBD3 
 
50.0  
 
6.3 
 
MccJ25 
 
>100.0 
 
6.3  
 
 
 
 
 
 
 
 
 
59 
 
6.2. Chemotaxis Assay 
HBD3 is chemotactic for human neutrophils [67]. The chemotaxis of bovine neutrophils in re-
sponse to HBD3, HBD3 20AA analogue, and HBD3 28AA analogue at 50.0 μg/ml was studied. 
Neutrophil migration in response to HBD3 and 20AA analogue was found to be statistically sig-
nificant when compared with PBS (Negative control), but the difference between PBS and 28AA 
was not significant (Figure 6.12). The result shows that HBD3 and HBD3 20AA analogue were 
chemotactic for bovine neutrophils at 50.0 μg/ml where as 28AA analogue was not.  
6.3. Migration Inhibition Assay 
Bovine neutrophils were treated with 50.0 μg/ml of HBD3, HBD3 20AA analogue, and HBD3 
28AA analogue and the effect of peptides on neutrophil migration towards fMLP was studied. 
Neutrophil migration towards fMLP when neutrophils were incubated with HBD3, HBD3 
20AA analogue, and HBD3 28AA analogues was statistically different from the PBS, which 
shows that none of the peptides inhibited migration of neutrophils towards fMLP (Figure 6.13). 
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Number of neutrophils that migrated in response to HBD3, HBD3 20AA analogue and, HBD3 
28AA analogue after 20 min incubation at 37
0
C. The three peptides were used at a concentration 
of 50.0 μg/ml. fMLP is the positive control. Mean±SEM of three independent experiments. One 
way ANOVA was followed by Dunnett’s multiple comparison test (P ≤ 0.0036). Asterisks show 
significant difference from PBS (Negative control) *P<0.05. 
  
Figure 6.12. Chemotaxis assay of the peptides against bovine neutrophils.  
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Number of neutrophils that migrated towards fMLP (114nM) after 20 min incubation at 37
0
C. 
Neutrophils were treated with 50.0 μg/ml HBD3, HBD3 20AA analogue and, HBD3 28AA ana-
logue. pn/f stands for peptide and neutrophils together in the upper well and fmlp in the bot-
tom during 20 min incubation. fMLP is the positive control. Mean±SEM of three independent 
experiments. One way ANOVA was followed by Dunnett’s multiple comparison test (P ≤ 
0.0036). Asterisks show significant difference from PBS (Negative control) *P<0.05. 
  
  Figure 6.13 Effect of peptides on neutrophil migration towards fMLP. 
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7. Discussion 
Our findings indicate that M. haemolytica is intermediately sensitive to HBD3 and its analogues. 
M. haemolytica shows resistance or at least intermediately sensitive to MccJ25. This classifica-
tion of peptide potency is arbitrary, “a strain was defined as sensitive to the peptide if MBC lev-
els were <10 μg/ml, as intermediately sensitive if MBC levels were 10 to 100 μg/ml, or as re-
sistant at MBC levels of >100 μg/ml” [88]. To our knowledge, this is the first study to test the 
killing and inhibitory effects of HBD3 and MccJ25 against M. haemolytica. Both peptides 
showed killing activity toward M. haemolytica as indicated by MBC and LD50 data, but peptides 
did not show inhibitory effect as seen in MIC data.  
In vitro susceptibility tests for cationic peptides are challenging to perfom because  polycationic 
peptides tend to precipitate and bind to the anionic surface of bacterial cells and plastic surface. 
There are data on the comparison of two methods for evaluating the in vitro antimicrobial activi-
ties of cationic AMP’s [89]. In the first method antimicrobial activity was evaluated according to 
the National Committee for Clinical Laboratory Standards (NCCLS) protocol using Polystyrene 
96-well plates that were incubated for 18 hours at 35°C in air [89]. The second method used was 
developed by R. E. W. Hancock for testing antimicrobial peptides where-in the Polypropylene 
96-well plates were incubated for 18 hours at 37°C in air. The comparative data showed that 
NCCLS protocol gave MICs and MBCs values that were four times higher than the method pro-
posed by Hancock [89].  
Polypropylene 96-well plates were used for antimicrobial evaluation to reduce the possibility of 
false higher MBCs and MICs as apparent in the results of Giacometti and the results of our pre-
liminary MIC experiment (data not shown). But, we used the NCCLS definition of MBC which 
describes the “minimal bactericidal concentration (MBC) as the lowest concentration of each 
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drug that resulted in a 99.9% reduction in CFU of the initial inoculum”. The R. E. W. Hancock 
considered the MBC as the “lowest concentration of each drug that prevented any residual colo-
ny formation”.  
We also carried out the minimum inhibitory concentration (MIC) assay (data not shown) using 
polypropylene 96-well plates. The only difference between the MBC assay and MIC assay was 
that after the bacteria in the wells were incubated with 50 µl of different concentrations of pep-
tides and incubated for 2 hours, the 50 μl BHI broth was put on the top of each well and then in-
cubated for another 18 hours. 
None of our five peptides inhibited visible growth of the M. haemolytica when compared with 
the positive control. The bactericidal nature of the cationic peptides could be the possible expla-
nation of these results. Ampicillin at a concentration of 24 μg/ml served as negative control in 
our experiments and there was no growth in the negative wells. Since there were 10000-25000 
bacteria/well and even if 0.1% of them survived and the peptide got consumed or deactivated 
over next few hours and media was still available for their growth. It is very likely that bacteria 
resumed growth to give false negatives. To ascertain the real cause we need to do time-kill stud-
ies. 
7.1. Peptide Selection, Synthesis and Antimicrobial evaluation. 
HBD3 and MccJ25 were selected as potential candidates. Wild-type HBD3 with purity ≥ 95% 
was obtained from AnaSpec Inc. The data contained in this thesis show synthesis and characteri-
zation of MccJ25 and three analogues of HBD3. We planned to synthesize HBD3 analogues 
namely 10AA (RGRKVVRRKK), 20AA (KEEQIGKVSTRGRKVVRRKK) & 30AA 
(GRVAVLSVLPKEEQIGKVSTRGRKV VRRKK), using Fmoc Solid Phase Peptide Synthesis. 
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The 10AA and 20AA analogue of HBD3 were synthesized successfully, whereas 30AA ana-
logue could not be synthesized.  Peptide showed correct mass (M+H
+ 
found 3386.4, calculated. 
3387) up to 28 amino acids during the test cleavage. However, addition of the last two amino 
acids followed by test cleavage did not show the desired mass. Amino acid chain could be elon-
gated up to only 28AA, as confirmed by MALDI-TOF even after repeated coupling. Mass spec. 
of 28AA crude peptide shows couple of other peaks along with 28AA analogue peak suggesting 
impurities in the crude peptide. The crude peptides (MccJ25, 10AA and 20AA analogue) were 
purified by RP-HPLC and then by MALDI-TOF mass spectrometry to confirm mass of the crude 
and pure peptides. 
7.1.1. MccJ25 
MccJ25 kills bacteria by inhibiting the RNA Polymerase (RNAP) but this microcin peptide has 
to enter the bacterial cell to accomplish this action. The MccJ5 sensitive strains have the trans-
porter proteins such as outer-membrane protein FhuA and the inner membrane protein SbmA to 
facilitate the transport of the antimicrobial peptides into the cells [90, 91]. It could be very likely 
that M. haemolytica does not possess such membrane proteins. Furthermore MccJ25 is resistant 
to many bacteria of the family Enterobacteriaceae that are not related to the MccJ25 producing 
members [92]. It could be argued that MccJ25 shows a narrow action spectrum activity in vitro.  
However, MccJ25 could be active in vivo against resistant species [92, 93]. It has been shown 
that resistant bacteria become susceptible to antibiotics upon their entry into phagolysosomes of 
macrophages. Most likely the low pH environment in the lysosomes of the macrophages leads to 
the nonspecific MccJ25 uptake into the bacterial cell through altered bacterial membrane perme-
ability. Also, MccJ25 has been shown to cause disruption of the membrane potential [93] and 
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hence it can be speculated that inside a macrophage M.haemolytica could become sensitive to 
MccJ25. 
7.1.2. HBD3 
In our study, HBD3 was very effective in killing M. haemolytica with MBC value of 50 μg/ml. 
The testing of the bactericidal activity of the HBD3 against 28 species and 55 strains of Gram-
positive cocci and Gram-negative fermentative and nonfermentative rods showed it be interme-
diately or highly effective [88]. However, MBC value in our study is higher when compared to 
the study done by Hany Sahly and colleagues in which only 3 strains out of 55 tested showed 
intermediate susceptibility (MBC value of 50.0 μg/ml), whereas rest of the strains were highly 
sensitive to HBD3 with MBC’s ranging from 0.1 to 6.3 μg/ml [88]. The reason for lower MBC’s 
in their study could be attributed to use of a lower final bacterial inoculum of 10
4
 to 10
5
/ml [88], 
compared 10
5 
to 10
6
/ml used in our study. This phenomenon of lower MBC corresponding with 
low final inoculum size was also observed in our study with 10AA analogue. We tested various 
concentrations of this analogue with final inoculum size of 10
4
 cells/ml of Mannehemia 
haemolytica and this gave us MBC of 6.3 μg/ml. 
7.1.3. HBD3 Analogues 
HBD3 analogues showed intermediate activity against our bacteria of interest. 20AA analogue 
was active against M. haemolytica in the same concentration as the wild type HBD3, after aver-
aging results from three different experiments, in duplicates, they showed equivalent MBC val-
ues.  
20 AA analogue’s potent activity can be attributed to its high positive charge (+9). HBD has a 
higher positive charge of +11 but showed anti-microbial activity similar to that of 20AA ana-
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logue. Therefore, it will be interesting to replace a couple of positively charged basic polar ami-
no acids such as arginine or lysine with valine, a neutral nonpolar amino acid, to the analogue 
more hydrophobic and increasingly selective for bacterial membranes. This argument is further 
supported by the fact that 10 AA analogue with +7 charge displayed excellent activity against M. 
haemolytica with 6.3 μg/ml as MBC when used with a small inoculum. The testing of this ana-
logue with a higher bacterial inoculum, similar to other peptides, would have further bolstered 
our results. Nevertheless, MBC of 10AA analogue was lower than both HBD3 and 20AA ana-
logue and therefore we may be able extrapolate this result for higher inoculum size. 
Zhou and Liu made eight C-terminal 10AA analogues of HBD3 replacing cysteines with either 
Valine, Tryptophan or Tyrosine. Out of these, Valine was easier to build via SPPS synthesis and 
was found to be most active [66]. They also made a dimer of Valine 10AA analogue, which 
turned out to be the most potent analogue. Instead of making a dimer of 10AA analogue, we 
chose to elongate the peptide chain up to 20 and 28 AA with mutation of all Cysteines with 
Valines. Both 20AA and 28AA analogues were active with 28AA peptide showing better activity 
than wild-type HBD3 [66]. These researchers further tested their peptides against Pseudomonas 
aeruginosa, a Gram –ve bacteria, in the same concentration range as ours. Comparing their study 
with ours, we found that the 10AA analogue had similar MBC values (50.0 μg/ml) for both 
Pseudomonas aeruginosa and M. haemolytica. However, their dimer was more potent than our 
20AA analogue.  
Studies have shown that some “C-terminal (R36-K45) analogues of human β-defensin-3 non-
covalently dimerize and adopt a well-defined structure in the aqueous solution and on the lipid 
bilayer” [66, 94]. Elucidating the underlying physico-chemical properties was beyond the scope 
of this study. However, we can speculate about the 3D structure of 20AA analogue based on the 
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nearly comparable MBC results of 20AA analogue with wtHBD3, and findings of the previous 
studies performed with NMR, fluorescence correlation spectroscopy and molecular dynamics 
simulation techniques [94]. 
It is possible that the 20AA analogue, dimerized both in aqueous solution and on the membrane 
surfaces, which tend to localize the positive charge density. Hence, it could be that the compact-
ness of positive charge and the growth of well defined structure once in solution accounts for the 
bactericidal efficacy of the 20AA analogue. Alternatively, the 20AA analogue would just remain 
as a linear monomer and its potent activity results from increased flexibility due to a loss of sec-
ondary structure. At this point we can not speculate about the structural conformation of 28AA 
analogue, since it was used in the crude form. Its activity could be a result of a truncated peptide.  
7.2. Chemotaxis and migration inhibition assay 
Anti-microbial peptides may exert a killing action against the microbes and they also may have a 
range of immunomodulatory functions such as modulating recruitment of neutrophils [64]. 
Defensins have also previously been studied for their chemotactic properties. Niyonsaba and col-
leagues tested the chemotaxis of human neutrophils towards HBD2 and HBD1 and found HBD2 
to be chemotactic [90]. To find out whether bovine neutrophils migrate in response to HBD3, 
20AA and 28AA analogue, we conducted chemotaxis assay using Boyden’s chamber. 
Similar to HBD2, the HBD3 and its 20AA analogue were found to be chemotactic in our exper-
iments. Previous data have shown that HBD2 was chemotactic only when the human neutrophils 
were pretreated with TNF-α [90]. Untreated neutrophils would not migrate in response to HBD-
2. But, in our study, we used only untreated bovine neutrophils and there was a significant mi-
gration in response to HBD3 and 20AA analogue when compared to the negative control 
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(P=0.0036). It could be a species specific phenomenon. Furthermore, we used the peptides at 
50.0 μg/ml and compared to concentrations of 0-10 μg/ml in previous studies [95]. It was earlier 
reported that cysteine mutated analogues of HBD3 might lose their chemotactic activity [67], but 
here 20AA analogue’s chemotactic behavior could be attributed to our use of higher concentra-
tion (50.0 μg/ml). To elucidate the chemotactic behavior of 20AA analogue it must be tested 
against a wide concentration range; neutrophils from other species should also be tested. 
It might be possible that bovine neutrophils are generally responsive to the Cysteine mutated 
HBD3 analogues. The data by Taylor and colleagues demonstrated the indispensability of three 
cysteine disulfide bridges for chemotactic activity [96]. They showed that HBD3 analogues lack-
ing disulfide bridges retained chemoattractant capability. HBD3 analogues which had cysteines 
replaced with alanines was devoid of any chemotactic activity. However, the chemotactic activi-
ty was not lost when the fifth cysteine was retained and other five were replaced. These anoma-
lous results could be due to variation in environmental conditions or different cell species used 
[96].  
Therefore, in the light of the new evidence it seems essential to do more studies to understand the 
relationship between structure and function of the HBD3 and its linear analogues with their 
chemotactic property. The chemotaxis in 28AA analogue well and PBS well was statistically not 
different. This anomaly can be accounted for if we take in to consideration that 28AA was in 
crude form and had contained a few truncated peptides. Lastly, the treatment of neutrophils with 
any of peptides did not affect their migration towards fMLP.  
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8.  LIMITATIONS OF THE STUDY 
I could not fully characterize the 28AA analogue and its activity could be the result of many 
truncated peptides. The use of manual SPSS process to synthesize the peptides in this study add-
ed significant amount of time to the work because automated peptide synthesizer for SPPS in our 
lab was out of order. This extra time could have been used for further anti-microbial and biologi-
cal characterization of the peptides.   
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9.  FUTURE STUDIES  
It will be useful to study the phagocytic activity of the immune cells such as neutrophils and 
macrophages that have been exposed to the anti-microbial peptides characterized in this study. 
Furthermore, the peptides should be evaluated against additional bacteria such as Histophilus 
somni that cause respiratory diseases in domestic animal species. There also is a need to deter-
mine whether the peptides affect the life-span or production of anti-microbial molecules such as 
reactive oxygen species or even affect their ability to migrate into diseased tissues; the later of 
course requires in vivo studies. 
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10.  CONCLUSIONS 
Three analogues of HBD3 were successfully synthesized and characterized. HBD3 and its 3 ana-
logues are active against M. haemolytica, but MccJ25 proved not very efficacious. HBD3 is 
chemotactic for bovine neutrophils at 50.0 µg/ml. HBD3 and 20AA did not inhibit migration of 
neutrophils. 
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